# US 2023/0056821 A1 · Use of fusion protein in treatment of age-related macular degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056821 A1
- Document ID: US20230056821A1
- Status: Published application
- Kind: A1
- Application number: 17/788,181
- Filed: 2020-12-23
- Published: 2023-02-23
- Earliest claimed: 2019-12-24
- Assignees: Innovent Biologics (Suzhou) Co., Ltd.
- Applicants: Innovent Biologics (Suzhou) Co., Ltd.
- Inventors: Shujie LU; Lei QIAN
- Web page: https://patentgrep.com/patent/US20230056821A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/18: against material from animals or humans
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to use of a fusion protein in the treatment of age-related macular degeneration. In particular, the present invention relates to use of a bispecific fusion protein inhibiting the activation of a complement pathway and a vascular endothelial growth factor (VEGF) pathway for the treatment of age-related macular degeneration. The present invention also relates to a pharmaceutical composition comprising the fusion protein and a method for treating age-related macular degeneration using the fusion protein.

## Claims

### Claim 1

A method for preventing or treating age-related macular degeneration (AMD) in an individual, comprising administering to the individual a fusion protein inhibiting a VEGF pathway and a complement pathway.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the sequence of the fusion protein is a sequence set forth in SEQ ID NO: 1.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein the AMD is wet AMD.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the wet AMD has one or more of the following symptoms and signs: visual acuity decrease, metamorphopsia, central scotoma, dyslexia, macular retinal swelling, fundus hemorrhage, neovascularization, scar fibrosis, geographic atrophy, or any combination thereof.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the wet AMD has choroidal neovascularization (CNV).

### Claim 7 (depends on 4)

The method according to claim 4, wherein the wet AMD is AMD having the following characteristics:
(1) active CNV under the macular fovea secondary to wet AMD occurs in a study eye; and/or
(2) central subfield thickness is ≥250 μm through optical coherence tomography (OCT) scanning.

### Claim 8

The method according to any one of the above claims, wherein the individual is a human individual having the disease, symptoms, and/or characteristics according to any one of the above claims.

### Claim 9

The method according to any one of the above claims, wherein the individual is a human individual who is a wet AMD patient accompanied by geographic atrophy.

### Claim 10

The method according to any one of the above claims, wherein the individual suffers from wet AMD with the following characteristics:
(1) active CNV under the macular fovea secondary to wet AMD occurs in a study eye; and/or
(2) central subfield thickness is ≥250 μm through optical coherence tomography (OCT) scanning.

### Claim 11

The method according to any one of the above claims, wherein the treatment can achieve one or more of the following effects in the individual:
1) central subfield thickness is decreased from a baseline;
2) area of the choroidal neovascularization (CNV) is reduced;
3) best corrected visual acuity (BCVA) is improved from a baseline;
4) onset of the geographic atrophy in the wet AMD patient is lagged; and/or
5) onset of the geographic atrophy in the wet AMD patient is slowed.

### Claim 12

The method according to any one of the above claims, wherein the treatment can achieve one or more of the following effects in the individual:
1) best corrected visual acuity (BCVA) is improved; and/or
2) central subfield thickness is decreased; and/or
3) choroidal neovascularization (CNV) area is reduced.

### Claim 13

The method according to any one of the above claims, wherein the treatment can achieve one or more of the following effects in the individual:
1) best corrected visual acuity (BCVA), as compared to a baseline, is improved by at least 1 ETDRS letter, preferably by at least 5 ETDRS letters, more preferably by 5-35 ETDRS letters, for example, by 5-25 ETDRS letters, for example, by 5-10, 5-15, 5-20, 10-15, 10-20, 10-25, 15-20 or 15-25 letters, for example, by 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 letters; and/or
2) best corrected visual acuity (BCVA), as compared to a baseline, is improved by 5% or more, preferably by 10% or more, for example, by 10%-200%, preferably by 10%-150%, more preferably by 10%-100%, more preferably by 20%-100%, more preferably by 50%-100%, 60%-100%, 20%-80% or 30%-70%, more preferably by 50%-70%, more preferably by 60%-70%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190% or 200%, and/or
3) central subfield thickness (CST), as compared to a baseline, is decreased by 25 μm or more, for example, by 25-350 μm, preferably by 50-300 μm, more preferably by 50-200 μm, for example, by 25 μm, 50 μm, 75 μm, 100 μm, 125 μm, 150 μm, 175 μm, 200 μm, 225 μm, 250 μm, 275 μm, 300 μm, 325 μm or 350 μm; or is decreased by 5% or more, for example, by 10%-70%, preferably by 10%-60%, more preferably by 30%-50%, more preferably by 40%-50%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70%; and/or
4) area of the choroidal neovascularization (CNV), as compared to a baseline, is reduced by 0.1 mm2 or more, for example, by 0.1-20 mm2, preferably by 0.2-5 mm2, more preferably by 0.3-2 mm2, for example, by 0.1 mm2, 0.2 mm2, 0.3 mm2, 0.4 mm2, 0.5 mm2, 0.6 mm2, 0.7 mm2, 0.8 mm2, 0.9 mm2, 1 mm2, 1.1 mm2, 1.2 mm2, 1.3 mm2, 1.4 mm2, 1.5 mm2, 1.6 mm2, 1.7 mm2, 1.8 mm2, 1.9 mm2, 2 mm2, 2.1 mm2, 2.2 mm2, 2.3 mm2, 2.4 mm2, 2.5 mm2, 2.6 mm2, 2.7 mm2, 2.8 mm2, 2.9 mm2, 3 mm2, 3.1 mm2, 3.2 mm2, 3.3 mm2, 3.4 mm2, 3.5 mm2, 3.6 mm2, 3.7 mm2, 3.8 mm2, 3.9 mm2, 4 mm2, 4.1 mm2, 4.2 mm2, 4.3 mm2, 4.4 mm2, 4.5 mm2, 4.6 mm2, 4.7 mm2, 4.8 mm2, 4.9 mm2, 5 mm2, 5.5 mm2, 6 mm2, 6.5 mm2, 7 mm2, 7.5 mm2, 8 mm2, 8.5 mm2, 9 mm2, 9.5 mm2, 10 mm2, 10.5 mm2, 11 mm2, 11.5 mm2, 12 mm2, 12.5 mm2, 13 mm2, 13.5 mm2, 14 mm2, 14.5 mm2, 15 mm2, 15.5 mm2, 16 mm2, 16.5 mm2, 17 mm2, 17.5 mm2, 18 mm2, 18.5 mm2, 19 mm2, 19.5 mm2 or 20 mm2; or is reduced by 5% or more, for example, by 10%-70%, preferably by 10%-60%, more preferably by 30%-50%, more preferably by 40%-50%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70%.

### Claim 14

The method according to any one of the above claims, comprising intravitreally or intravenously administering to the individual the fusion protein at a single dose of about 0.01-10 mg/eye, preferably 0.05-8 mg/eye, more preferably 0.05-6 mg/eye, more preferably 0.5-5 mg/eye, more preferably 1-5 mg/eye, more preferably 2-5 mg/eye once a day, once every two days, twice a week, once a week, once every two weeks, once every four weeks, once every five weeks or once every six weeks, wherein central subfield thickness of the individual six or eight weeks after administration, as compared to central subfield thickness of the individual before administration, is decreased by 25 μm or more, for example, by 25-350 μm, preferably by 50-300 μm, more preferably by 50-200 μm, for example, by 25 μm, 50 μm, 75 μm, 100 μm, 125 μm, 150 μm, 175 μm, 200 μm, 225 μm, 250 μm, 275 μm, 300 μm, 325 μm or 350 μm; or is decreased by 5% or more, for example, by 10%-70%, preferably by 10%-60%, more preferably by 30%-50%, more preferably by 40%-50%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70%.

### Claim 15

The method according to any one of the above claims, comprising intravitreally or intravenously administering to the individual the fusion protein at a single dose of about 0.01-10 mg/eye, preferably 0.05-8 mg/eye, more preferably 0.05-6 mg/eye, more preferably 0.5-5 mg/eye, more preferably 1-5 mg/eye, more preferably 2-5 mg/eye once a day, once every two days, twice a week, once a week, once every two weeks, once every four weeks, once every five weeks or once every six weeks, wherein area of the choroidal neovascularization (CNV) of the individual six or eight weeks after administration, as compared to area of the choroidal neovascularization (CNV) of the individual before administration, is reduced by more than 0.1 mm2, for example, by 0.1-20 mm2, preferably by 0.2-5 mm2, more preferably by 0.3-2 mm2, for example, by 0.1 mm2, 0.2 mm2, 0.3 mm2, 0.4 mm2, 0.5 mm2, 0.6 mm2, 0.7 mm2, 0.8 mm2, 0.9 mm2, 1 mm2, 1.1 mm2, 1.2 mm2, 1.3 mm2, 1.4 mm2, 1.5 mm2, 1.6 mm2, 1.7 mm2, 1.8 mm2, 1.9 mm2, 2 mm2, 2.1 mm2, 2.2 mm2, 2.3 mm2, 2.4 mm2, 2.5 mm2, 2.6 mm2, 2.7 mm2, 2.8 mm2, 2.9 mm2, 3 mm2, 3.1 mm2, 3.2 mm2, 3.3 mm2, 3.4 mm2, 3.5 mm2, 3.6 mm2, 3.7 mm2, 3.8 mm2, 3.9 mm2, 4 mm2, 4.1 mm2, 4.2 mm2, 4.3 mm2, 4.4 mm2, 4.5 mm2, 4.6 mm2, 4.7 mm2, 4.8 mm2, 4.9 mm2, 5 mm2, 5.5 mm2, 6 mm2, 6.5 mm2, 7 mm2, 7.5 mm2, 8 mm2, 8.5 mm2, 9 mm2, 9.5 mm2, 10 mm2, 10.5 mm2, 11 mm2, 11.5 mm2, 12 mm2, 12.5 mm2, 13 mm2, 13.5 mm2, 14 mm2, 14.5 mm2, 15 mm2, 15.5 mm2, 16 mm2, 16.5 mm2, 17 mm2, 17.5 mm2, 18 mm2, 18.5 mm2, 19 mm2, 19.5 mm2 or 20 mm2; or is reduced by 5% or more, for example, by 10%-70%, preferably by 10%-60%, more preferably by 30%-50%, more preferably by 40%-50%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or 70%.

### Claim 16

The method according to any one of the above claims, comprising intravitreally or intravenously administering to the individual the fusion protein at a single dose of about 0.01-10 mg/eye, preferably 0.05-8 mg/eye, more preferably 0.05-6 mg/eye, more preferably 0.5-5 mg/eye, more preferably 1-5 mg/eye, more preferably 2-5 mg/eye once a day, once every two days, twice a week, once a week, once every two weeks, once every four weeks, once every five weeks or once every six weeks, wherein best corrected visual acuity (BCVA) of the individual six or eight weeks after administration, as compared to best corrected visual acuity (BCVA) of the individual before administration, is improved by at least 1 ETDRS letter, preferably by at least 5 ETDRS letters, more preferably by 5-35 ETDRS letters, for example, by 5-25 ETDRS letters, for example, by 5-10, 5-15, 5-20, 10-15, 10-20, 10-25, 15-20 or 15-25 letters, for example, by 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 letters; or is improved by 5% or more, preferably by 10% or more, for example, by 10%-200%, preferably by 10%-150%, more preferably by 10%-100%, more preferably by 20%-100%, more preferably by 50%-100%, 60%-100%, 20%-80% or 30%-70%, more preferably by 50%-70%, more preferably by 60%-70%, for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190% or 200%.

### Claim 17

Use of the fusion protein inhibiting a VEGF pathway and a complement pathway in the manufacture of a medicament for preventing or treating age-related macular degeneration (AMD) in an individual, wherein the fusion protein comprises a sequence of SEQ ID NO: 1.

### Claim 18 (depends on 17)

The use according to claim 17, wherein the sequence of the fusion protein is a sequence set forth in SEQ ID NO: 1.

### Claim 19 (depends on 4, 5, 6, 7, 17, 18)

The use according to any one of claims 17-18, wherein the AMD is as defined in any one of claims 4-7.

### Claim 20 (depends on 8, 9, 10, 17, 18, 19)

The use according to any one of claims 17-19, wherein the individual is as defined in any one of claims 8-10.

### Claim 21

A single pharmaceutical dosage unit, comprising a fusion protein inhibiting a VEGF pathway and a complement pathway, wherein the fusion protein comprises a sequence of SEQ ID NO: 1.

### Claim 22 (depends on 21)

The single pharmaceutical dosage unit according to claim 21, wherein the sequence of the fusion protein is a sequence set forth in SEQ ID NO: 1.

### Claim 23 (depends on 21, 22)

The single pharmaceutical dosage unit according to claim 21 or 22, comprising the fusion protein at the following doses: 0.01-10 mg, preferably 0.05-8 mg, more preferably 0.05-6 mg, more preferably 0.5-5 mg, more preferably 1-5 mg, more preferably 2-5 mg, for example, 0.5-2 mg, 1-3 mg, 2-4 mg, 2-3 mg or 3-5 mg, for example, 0.05 mg, 0.1 mg, 0.15 mg, 0.2 mg, 0.25 mg, 0.3 mg, 0.35 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.55 mg, 0.6 mg, 0.65 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.85 mg, 0.9 mg, 0.95 mg, 1 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg, 3 mg, 3.1 mg, 3.2 mg, 3.3 mg, 3.4 mg, 3.5 mg, 3.6 mg, 3.7 mg, 3.8 mg, 3.9 mg, 4 mg, 4.1 mg, 4.2 mg, 4.3 mg, 4.4 mg, 4.5 mg, 4.6 mg, 4.7 mg, 4.8 mg, 4.9 mg, 5 mg, 5.1 mg, 5.2 mg, 5.3 mg, 5.4 mg, 5.5 mg, 5.6 mg, 5.7 mg, 5.8 mg, 5.9 mg, 6 mg, 6.1 mg, 6.2 mg, 6.3 mg, 6.4 mg, 6.5 mg, 6.6 mg, 6.7 mg, 6.8 mg, 6.9 mg, 7 mg, 7.1 mg, 7.2 mg, 7.3 mg, 7.4 mg, 7.5 mg, 7.6 mg, 7.7 mg, 7.8 mg, 7.9 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg or 10 mg, preferably 2 mg or 4 mg.

### Claim 24 (depends on 21, 22, 23)

A pharmaceutical kit, comprising the fusion protein according to any one of claims 21-23.

### Claim 25 (depends on 21, 22, 23, 24)

Use of the single pharmaceutical dosage unit according to any one of claims 21-23 or the pharmaceutical kit according to claim 24 in the manufacture of a medicament for preventing or treating age-related macular degeneration (AMD).

### Claim 26 (depends on 21, 22, 23, 24)

The single pharmaceutical dosage unit according to any one of claims 21-23 or the pharmaceutical kit according to claim 24, for use in the prevention or treatment of age-related macular degeneration (AMD).
